Low-dose chemo may keep breast cancer under control


Rather than try to wipe out cancer with powerful doses of chemotherapy, researchers said Wednesday an experimental approach using lower amounts of medication may work better to keep tumours under control.

Toxic effects

The study was done on mice with breast cancer, according to the report in Science Translational Medicine, and is part of a growing movement in oncology to explore alternatives to high-dose chemo and its often toxic side effects.

"Our results suggest that this adaptive therapeutic strategy... can result in prolonged progression-free survival in breast cancer," said the study, authored by Pedro Enriquez-Navas and colleagues at the H. Lee Moffitt Cancer Centre and Research Institute in Tampa, Florida.

Read: Nipple-sparing mastectomy as good as full surgery

Some researchers question the use of standard chemotherapy because it rarely wipes out cancer entirely, and leaves behind drug-resistant cells that can take over and lead to an explosion in tumour growth.

The new approach delivers continuous low-dose chemotherapy – in this case paclitaxel – that stabilises the tumour by "maintaining a small population of drug-sensitive tumour cells to suppress the growth of resistant cells," said the study.

Standard doses of paclitaxel in mice shrunk breast tumours, but these tumours grew back once the treatment ended.

Read: Breast self-examination

"Another treatment regimen that skips doses whenever the tumour shrinks also inevitably resulted in tumour progression," said the study.

"In contrast, adaptive therapy consisting of high initial drug doses followed by progressively lower doses as the tumour responded was more effective in controlling tumour growth than either standard therapy or dose skipping."

Read: New breast cancer drug shows 'unprecedented' results

The study found that 60 to 80 percent of the mice treated by adaptive therapy could be "weaned off the drug completely without relapsing for an extended period of time".

More research is needed before the approach can be recommended for use in people. However, the research offers "a very good possibility for future therapies", Giannoula Klement, of the Tufts University School of Medicine in Boston, wrote in an accompanying editorial.

"More and more oncologists are engaging some version of this approach." 

Read more: 

What is breast cancer? 

Symptoms of breast cancer  

Preventing breast cancer  

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
The ANC's leadership race is heating up. Who do you think will be elected party president at Nasrec in December?
Please select an option Oops! Something went wrong, please try again later.
Nkosazana Dlamini-Zuma has got it in the bag
6% - 322 votes
I foresee a second term for Cyril Ramaphosa
82% - 4068 votes
Don’t discount a Zweli Mkhize win
12% - 590 votes
Rand - Dollar
Rand - Pound
Rand - Euro
Rand - Aus dollar
Rand - Yen
Brent Crude
Top 40
All Share
Resource 10
Industrial 25
Financial 15
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.